Generate Biomedicines (NASDAQ:GENB) Coverage Initiated by Analysts at Guggenheim

Equities research analysts at Guggenheim initiated coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a report released on Tuesday,Benzinga reports. The firm set a “buy” rating and a $30.00 price target on the stock. Guggenheim’s price objective suggests a potential upside of 139.62% from the stock’s current price.

Several other analysts have also recently weighed in on GENB. Wall Street Zen raised shares of Generate Biomedicines to a “hold” rating in a research note on Saturday, March 14th. Cantor Fitzgerald started coverage on Generate Biomedicines in a report on Tuesday. They issued an “overweight” rating on the stock. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $30.00.

Generate Biomedicines Price Performance

Shares of Generate Biomedicines stock opened at $12.52 on Tuesday. Generate Biomedicines has a 12-month low of $11.00 and a 12-month high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.